Related Experiment Video
Updated: Jan 26, 2026
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Detecting the mutational signature of homologous recombination deficiency in clinical samples
Doga C Gulhan1, Jake June-Koo Lee1, Giorgio E M Melloni1
1Department of Biomedical Informatics and Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.
Abstract:
Mutations in BRCA1 and/or BRCA2 (BRCA1/2) are the most common indication of deficiency in the homologous recombination (HR) DNA repair pathway. However, recent genome-wide analyses have shown that the same pattern of mutations found in BRCA1/2-mutant tumors is also present in several other tumors. Here, we present a new computational tool called Signature Multivariate Analysis (SigMA), which can be used to accurately detect the mutational signature associated with HR deficiency from targeted gene panels. Whereas previous methods require whole-genome or whole-exome data, our method detects the HR-deficiency signature even from low mutation counts, by using a likelihood-based measure combined with machine-learning techniques. Cell lines that we identify as HR deficient show a significant response to poly (ADP-ribose) polymerase (PARP) inhibitors; patients with ovarian cancer whom we found to be HR deficient show a significantly longer overall survival with platinum regimens. By enabling panel-based identification of mutational signatures, our method substantially increases the number of patients that may be considered for treatments targeting HR deficiency.
Insights
A new tool, Signature Multivariate Analysis (SigMA), identifies homologous recombination (HR) deficiency signatures from gene panels. This advances cancer treatment by enabling more patients to receive targeted therapies like PARP inhibitors.
Area of Science:
- Genomics
- Computational Biology
- Cancer Research
Background:
- Mutations in BRCA1 and/or BRCA2 (BRCA1/2) are primary indicators of homologous recombination (HR) DNA repair pathway deficiency.
- Genome-wide studies reveal similar mutational patterns in non-BRCA1/2 tumors, suggesting broader HR deficiency.
Purpose of the Study:
- To introduce Signature Multivariate Analysis (SigMA), a computational tool for detecting HR deficiency mutational signatures.
- To enable HR deficiency detection from targeted gene panels, overcoming limitations of whole-genome/exome data requirements.
Main Methods:
- Utilizes a likelihood-based measure combined with machine-learning techniques.
- Analyzes targeted gene panels to identify HR-deficiency signatures, even with low mutation counts.
Main Results:
- Identified HR-deficient cell lines demonstrated significant responsiveness to poly (ADP-ribose) polymerase (PARP) inhibitors.
- HR-deficient ovarian cancer patients exhibited significantly longer overall survival when treated with platinum regimens.
Conclusions:
- SigMA facilitates panel-based identification of mutational signatures indicative of HR deficiency.
- This method expands the patient population eligible for HR deficiency-targeted therapies, improving treatment strategies.
Related Concept Videos
02:31Homologous Recombination
02:31Homologous Recombination
01:39Mutations
01:35Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
01:09Recombinant DNA
00:36Viral Mutations